Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous lidocaine for symptoms of COVID-19
NL-OMON49145Phase 3Withdrawn
- Sponsor
- Julius Clinical
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Lidocaine plus standard of care with Standard of care (2 arms). Primary endpoint: Clinical improvement within 5 days after randomization. Planned start May 2020; status: withdrawn.
02
Drugs
lidocaine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON49145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49145.